<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063541</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT-U_V2.2_20_Feb_2017</org_study_id>
    <secondary_id>2017-000514-35</secondary_id>
    <nct_id>NCT03063541</nct_id>
  </id_info>
  <brief_title>Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms</brief_title>
  <acronym>PROTECT-U</acronym>
  <official_title>Prospective Randomized Open-label Trial to Evaluate Risk faCTor Management in Patients With Unruptured Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schwiete Stiftung, Mannheim, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to assess the hypothesis that a strategy with acetylsalicylic acid
      (ASA) 100 mg/day, intensive blood pressure treatment (targeted systolic blood pressure below
      120 mmHg), and a blood pressure measuring device reduces the risk of aneurysm rupture or
      growth compared with standard care (i.e. no ASA, blood pressure management according to
      standard blood pressure management, no blood pressure measuring device)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>controlled open trial, randomized 1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>observer blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>aneurysm rupture or growth</measure>
    <time_frame>36 months</time_frame>
    <description>aneurysm rupture (i.e. aneurysmal subarachnoid hemorrhage, SAH) or growth (increase in any aneurysm diameter by ≥1mm) on serial imaging (either two MR or CT angiographies)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aneurysm volume</measure>
    <time_frame>36 months</time_frame>
    <description>difference of aneurysm volume (in computerized measurements defined as increase of aneurysm volume in computerized measurements by &gt;10% and &gt;3mm3 or aneurysm shape (e.g. development of daughter sac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new aneurysm</measure>
    <time_frame>36 months</time_frame>
    <description>development of de novo aneurysm on serial imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>therapy of aneurysm</measure>
    <time_frame>36 months</time_frame>
    <description>clipping/coiling during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>36 months</time_frame>
    <description>any ischemic or haemorrhagic stroke, defined as clinical symptoms for stroke AND a compatible lesion on imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocard infarction</measure>
    <time_frame>36 months</time_frame>
    <description>myocardial infarction defined as increase of troponin, creatine-kinase MB and/or presence of new significant Q waves obtained in electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular death</measure>
    <time_frame>36 months</time_frame>
    <description>vascular death (including fatal stroke, fatal myocardial infarction, sudden death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>36 months</time_frame>
    <description>major spontaneous bleeding requiring hospitalisation defined as substantially disabling bleeding, intraocular bleeding leading to the loss of vision, or bleeding necessitating the transfusion of at least 2 units of erythrocyte concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>36 months</time_frame>
    <description>death from all other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>achieved blood pressure</measure>
    <time_frame>36 months</time_frame>
    <description>any data on blood pressure management used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse and Serious Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>all adverse and serious adverse events related to the experimental intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">776</enrollment>
  <condition>Unruptured Intracranial Aneurysms</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blood pressure management according to guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>100 mg daily as one tablet</description>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intensive blood pressure control</intervention_name>
    <description>Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.</description>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older with an intradural, saccular unruptured aneurysm (UIA) in
             whom it is decided not to intervene with preventive endovascular or neurosurgical
             repair of the aneurysm and who are monitored on a regular base for aneurysm growth

          -  Last aneurysm imaging with either CTA/MRA/DSA within the last 3 months

        Exclusion Criteria:

          -  All non-saccular UIAs or aneurysms related to arteriovenous malformations

          -  Frequent ASA use and/or indication for a vitamin K antagonist, or direct oral
             anticoagulant (DOAC) treatment at baseline

          -  Contra-indication for ASA

          -  History of hypersensitivity to ASA or to any other drug with similar chemical
             structure or to any excipient present in the pharmaceutical form of ASA

          -  Chronic kidney disease stage IV and V (GFR &lt; 30 mL/min/1.73 m2)

          -  Pregnancy and lactation

          -  Participation in another clinical trial or observation period of competing trials,
             respectively

          -  Life-expectancy &lt;3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nima Etminan, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMM, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mervyn D Vergouwen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht, Department of Neurology and Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nima Etminan, PD Dr. med.</last_name>
    <phone>+49 621 383-2360</phone>
    <email>Nima.Etminan@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mervyn DI Vergouwen, M.D., Ph.D.</last_name>
    <phone>+31 88 75 50455</phone>
    <email>M.D.I.Vergouwen@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology and Neurosurgery, Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmuth Steinmetz, Prof. Dr.</last_name>
      <phone>+49 69 6301-5769</phone>
      <email>helmuth.steinmetz@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Konczalla, PD Dr</last_name>
      <email>J.Konczalla@med.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmuth Steinmetz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit A Schubert, Prof. Dr.</last_name>
      <phone>+49 241 8082420</phone>
      <email>gschubert@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Rastislav Pjontek, Dr.</last_name>
      <email>rpjontek@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerrit A Schubert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vajkoczy, Prof. Dr.</last_name>
      <phone>+49 30 450 560900</phone>
      <email>peter.vajkoczy@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lars Wessels, Dr.</last_name>
      <phone>030 450 56</phone>
      <phone_ext>0002</phone_ext>
      <email>lars.wessels@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Vajkoczy, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Petridis, Prof. Dr.</last_name>
      <phone>+49 211810</phone>
      <phone_ext>4514</phone_ext>
      <email>athanasios.petridis@duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerim Beseoglu, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neurolgische Klinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagen Huttner, Prof. Dr.</last_name>
      <phone>+4991318536597</phone>
      <email>hagen.huttner@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kallmünzer, Dr.</last_name>
      <email>bernd.kallmuenzer@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hagen Huttner, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramazan Jabbarli, PD Dr.</last_name>
      <email>ramazan.jabbarli@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ramazan Jabbarli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie</name>
      <address>
        <city>Göttingen</city>
        <zip>37037</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothe Mielke, Prof. Dr.</last_name>
      <email>dorothe.mielke@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Lange</last_name>
      <email>katharina.lange@med.uni-goettingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Veit Rohde, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurochirurgie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils O Schmidt, PD Dr.</last_name>
      <email>nschmidt@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Jan Regelsberger, Prof. Dr.</last_name>
      <email>j.regelsberger@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nils O Schmidt, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A Ringleb, Prof. Dr.</last_name>
      <phone>+496221 56-</phone>
      <phone_ext>8243</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Beyrle</last_name>
      <phone>+406221 563-</phone>
      <phone_ext>8856</phone_ext>
      <email>elisabeth.beyrle@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter A Ringleb, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nima Etminan, PD Dr. med.</last_name>
      <phone>+49-621-383-2360</phone>
      <email>nima.etminan@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Hackenberg, Dr.med.</last_name>
      <phone>+49-621-383-2360</phone>
      <email>katharina.hackenberg@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nima Etminan, PD Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Haenggi, Prof. Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurochirurgische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Holling, MD PhD</last_name>
      <phone>+49 251 / 83 -47482</phone>
      <email>hollingm@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Markus Holling, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Department of Neurology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvo B. W. Roos, Prof. Dr.</last_name>
      <phone>+31-20-5663942</phone>
      <email>y.b.roos@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Rita Sprengers</last_name>
      <email>r.g.sprengers@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Yvo Roos, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maarten Uyttenboogaart, Dr.</last_name>
      <email>m.uyttenboogaart@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Maarten Uyttenboogaart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine Holswilder, MD</last_name>
      <email>g.holswilder@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>A van der Meij, MD</last_name>
      <email>a.van_der_meij@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marieke JH Wermer, MD PhD FESO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurochirurgisch Centrum CWZ</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 GS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Boogaarts, Dr.</last_name>
      <email>jeroen.boogaarts@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Viktoria Shimanskaya, Dr</last_name>
      <email>vika.shimanskaya@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jeroen Boogarts, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naziha el Ghannouti</last_name>
      <phone>+31 10 704 38 18</phone>
      <email>n.elghannouti@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bob Roozenbeek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mervyn D. I. Vergouwen, Dr.</last_name>
      <phone>+31 (0)88 755 0455</phone>
      <email>M.D.I.Vergouwen@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jacco M. Westeneng</last_name>
      <email>J.M.Westeneng-4@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Mervyn D. I. Vergouwen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Vergouwen MD, Rinkel GJ, Algra A, Fiehler J, Steinmetz H, Vajkoczy P, Rutten FH, Luntz S, Hänggi D, Etminan N. Prospective Randomized Open-label Trial to evaluate risk faCTor management in patients with Unruptured intracranial aneurysms: Study protocol. Int J Stroke. 2018 Dec;13(9):992-998. doi: 10.1177/1747493018790033. Epub 2018 Jul 18.</citation>
    <PMID>30019634</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Nima Etminan</investigator_full_name>
    <investigator_title>Vice Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

